Vor Bio appoints Jeremy Sokolove CMO; amends CDO severance terms

Vor Biopharma Inc.

Dr. Jeremy Sokolove appointed CMO effective Nov 3, 2025; has >20 yrs rheumatology/autoimmune R&D experience.
Sokolove previously CMO-in-Residence at Roivant Sciences, SVP at GSK, Head of Immunology at AbbVie.
Vor Bio emphasizes Telitacicept (dual BAFF/APRIL inhibitor) as near-term opportunity for autoimmune patients.
Amended CDO Dr. Qing Zuraw's severance: pro-rated 2025/2026 target bonus if terminated w/o cause, or if resigns after Dec 31, 2025.
Employment amendment effective for five months from Nov 2, 2025.

item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.